Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02200848 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
A Phase 1 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02200848 is a Phase 1 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 5 participants.
The verdict
NCT02200848, a Phase 1 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is for subjects diagnosed with recurrent or relapsed CLL/SLL. The purpose of this study is to test the safety of the combination of the drugs lenalidomide and ibrutinib at different dose levels, in combination with the drug rituximab. We want to find out what effects, good and/or bad, they have on patients with CLL/SLL. The hypothesis of the study is that it will be safe to give the three drugs in combination and the information learned from this trial will be used to study the 3 drug combination is a larger future trial.
Interventions
- DRUG Lenalidomide, Ibrutinib, Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-04 |
| Est. Completion | 2017-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02200848
The ClinicalTrials.gov registry entry for NCT02200848 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide, Ibrutinib, Rituximab is the first listed.
NCT02200848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02200848 about?
NCT02200848 is a clinical study titled "Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)". This study is for subjects diagnosed with recurrent or relapsed CLL/SLL. The purpose of this study is to test the safety of the combination of the drugs lenalidomide and ibrutinib at different dose levels, in combination with the drug rituximab. We want to find out what effects, good and/or bad, the...
What is the current status of trial NCT02200848?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2014-04. Estimated completion is 2017-08-01.
What interventions are being tested in trial NCT02200848?
The interventions under investigation include: Lenalidomide, Ibrutinib, Rituximab (DRUG).
Who is sponsoring clinical trial NCT02200848?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.